InVitria Reports Expanded Manufacturing Capability to Meet Commercial Demand for Lysobac, an Animal Free Reagent for Bacterial FermentationInVitria’s Lysobac is a high potency, animal free and consistent alternative to chicken lysozyme, which is used in bacterial cell lysis. Tests prove Lysobac is greater than 4 times more active than chicken lysozyme and increases protein yield from bacterial fermentation.
Now, InVitria will meet the demand of large commercial users who require metric ton quantities of bacterial cell lysis reagents. "With the increase in production capacity at our ISO 9001 facility, we now have the ability to supply large volumes of Lysobac to commercial customers all over the world," said Greg Unruh, Vice President of Production.
"InVitria customers have achieved significant performance and safety benefits from using Lysobac as a cell lysis reagent," said Scott Deeter, President and CEO. "Further, Lysobac allows manufacturers to switch to an animal free production system and avoid the risk of contaminants from animal derived components," said Deeter.
Lysobac offers substantial advantages over chicken lysozyme and mechanical lysis, including:
Through December 1, 2009, InVitria is offering a FREE Papa John’s Pizza gift card for all Lysobac orders placed through InVitria’s WebStore. Visit www.lysobac.com to place your order.
About InVitria (See www.InVitria.com)
For more information about InVitria’s products, please contact InVitria’s Product Support team at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
